$东阳光长江药业(0_老虎社区_美港股上老虎

$东阳光长江药业(01558)$ 中国创新药License-out交易规模持续扩大，2025年三生制药与辉瑞的60亿美元交易验证了国产创新药的国际认可度。伊非尼酮作为国产原研药，可能成为跨国药企争夺的BD标的，进一步释放其商业价值

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":446925853610000,"tweetId":"446925853610000","gmtCreate":1750134241393,"gmtModify":1750134244396,"author":{"id":4107239966895660,"idStr":"4107239966895660","authorId":4107239966895660,"authorIdStr":"4107239966895660","name":"向阳花之光","avatar":"https://static.tigerbbs.com/e322d38c22fa6cc88f0c102424c4a365","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/01558\">$东阳光长江药业(01558)$ &nbsp;</a>中国创新药License-out交易规模持续扩大，2025年三生制药与辉瑞的60亿美元交易验证了国产创新药的国际认可度。伊非尼酮作为国产原研药，可能成为跨国药企争夺的BD标的，进一步释放其商业价值</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/01558\">$东阳光长江药业(01558)$ &nbsp;</a>中国创新药License-out交易规模持续扩大，2025年三生制药与辉瑞的60亿美元交易验证了国产创新药的国际认可度。伊非尼酮作为国产原研药，可能成为跨国药企争夺的BD标的，进一步释放其商业价值</p></body></html>","text":"$东阳光长江药业(01558)$ 中国创新药License-out交易规模持续扩大，2025年三生制药与辉瑞的60亿美元交易验证了国产创新药的国际认可度。伊非尼酮作为国产原研药，可能成为跨国药企争夺的BD标的，进一步释放其商业价值","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/446925853610000","repostId":0,"isVote":1,"tweetType":1,"viewCount":2233,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["01558"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":196,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}